Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EP395 in healthy volunteers with inhaled endotoxin challenge
NCT06677918Phase 1Completed
- Sponsor
- EpiEndo Pharmaceuticals
- Start
- Feb 2025
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial comparing EP395 with Placebo (2 arms). Primary endpoint: Blood Surfactant Protein-D at Day 21. Started Feb 2025; status: completed.
02
Drugs
glasmacinal
Beyond the preview
Go deeper on NCT06677918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06677918.